Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Urtasun, R. C.
Right arrow Articles by Sturmwind, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urtasun, R. C.
Right arrow Articles by Sturmwind, J.

Radiology, Vol 117, 129-133, Copyright © 1975 by Radiological Society of North America

ARTICLES

Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells

RC Urtasun, JD Chapman, P Band, HR Rabin, CG Fryer and J Sturmwind

Metronidazole was administered orally to 25 patients and its maximum concentration in blood and tumor tissues, its ability to cross the blood/brain barrier and concentrate in the cerebrospinal fluid and brain tumor tissue, its immediate and long-term toxicity, and its enhancement of irradiation in normal tissue were studied. Maximum blood concentrations of 700-1,200 muM (120-220 mug/ml) were obtained at four hours with doses of 6 g/m2. Moderate and transient nausea and vomiting were the only immediate signs of toxicity. No long-term toxicity was found up to 18 months after administration of the drug. These data indicate that metronidazole can feasibly be adminstered in clinical trials of fractionated radiotherapy using dosages ranging from 9.5 to 11 g three times a week for three to four weeks.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. M. Seddon, G. S. Payne, L. Simmons, R. Ruddle, R. Grimshaw, S. Tan, A. Turner, F. Raynaud, G. Halbert, M. O. Leach, et al.
A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy
Clin. Cancer Res., November 1, 2003; 9(14): 5101 - 5112.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. FRYTAK, C. G. MOERTEL, D. S. CHILDS, and J. W. ALBERS
Neurologic Toxicity Associated with High-Dose Metronidazole Therapy
Ann Intern Med, March 1, 1978; 88(3): 361 - 362.
[Abstract] [PDF]